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Key messages
What is the key question?
 ► Does National Early Warning Score 2 (NEWS2) 
reduce alert frequency, and offer superior 
prognostic performance to other versions of 
NEWS and the DECAF (dyspnoea, eosinopenia, 
consolidation, acidaemia, atrial fibrillation) 
score in 2645 patients admitted with COPD 
exacerbation who have spirometry-proven 
COPD?
What is the bottom line?
 ► NEWS2 is superior to the original NEWS, but 
using the second oxygen scale within NEWS2 
(target oxygen saturations 88%–92%) in all 
patients with COPD exacerbation substantially 
reduces false alerts without increased risk. 
DECAF offers superior risk-stratification on 
admission, but does not replace early warning 
scores to detect subsequent deterioration.
Why read on?
 ► Our data support monitoring all patients 
with COPD exacerbation using the second 
NEWS2 oxygen scale, and this advice should 
override the current Royal College of Physicians 
recommendation that the second scale should 
only be used in hypercapnic patients and at the 
discretion of a clinician.
AbsTrACT
background the national early Warning Score 2 
(neWS2) includes two oxygen saturation scales; the 
second adjusts target saturations to 88%–92% for those 
with hypercapnic respiratory failure. Using this second 
scale in all patients with cOPD exacerbation (’neWS2all 
cOPD’) would simplify practice, but the impact on alert 
frequency and prognostic performance is unknown. 
admission neWS2 score has not been compared 
with DecaF (dyspnoea, eosinopenia, consolidation, 
acidaemia, atrial fibrillation) for inpatient mortality 
prediction.
Methods neWS, neWS2 and neWS2all cOPD and DecaF 
were calculated at admission in 2645 patients with 
cOPD exacerbation attending consecutively to one of 
six UK hospitals, all of whom met spirometry criteria 
for cOPD. alert frequency and appropriateness were 
assessed for all neWS iterations. Prognostic performance 
was compared using the area under the receiver 
operating characteristic (aUrOc) curve. Missing data 
were imputed using multiple imputation.
Findings compared with neWS, neWS2 reclassified 
3.1% patients as not requiring review by a senior 
clinician (score≥5). neWS2all cOPD reduced alerts by 
12.6%, or 16.1% if scoring for injudicious use of oxygen 
was exempted. Mortality was low in reclassified patients, 
with no patients dying the same day as being identified 
as low risk. neWS2all cOPD was a better prognostic score 
than neWS (aUrOc 0.72 vs 0.65, p<0.001), with 
similar performance to neWS2 (aUrOc 0.72 vs 0.70, 
p=0.090). DecaF was superior to all scores (validation 
cohort aUrOc 0.82) and offered a more clinically useful 
range of risk stratification (DecaF=1.2%–25.5%; 
neWS2=3.5%–15.4%).
Conclusion neWS2all cOPD safely reduces the alert 
frequency compared with neWS2. DecaF offers superior 
prognostic performance to guide clinical decision-making 
on admission, but does not replace repeated measures of 
neWS2 during hospitalisation to detect the deteriorating 
patient.
bACKground
The National Early Warning Score (NEWS) facil-
itates prompt recognition of clinical deterioration 
in patients hospitalised with a wide range of condi-
tions.1 It is composed of bedside indices (respiratory 
rate, oxygen saturations, systolic blood pressure, 
pulse, level of consciousness and temperature) with 
clear thresholds commanding the urgency of clin-
ical response. Early warning scores, such as NEWS, 
are intended to be scored repeatedly during the 
inpatient stay to monitor patients for deterioration.
Although NEWS is widely used in the UK, 
two key limitations have been highlighted. First, 
patients with COPD and chronic hypoxaemia raise 
false alerts, which may lead to alert fatigue and 
complacency. Second, in severe COPD exacerba-
tions (ECOPD), excess oxygen is associated with 
increased need for ventilation and mortality,2–4 but 
this risk is not identified by NEWS,5 6 which may 
encourage unsafe oxygen prescribing to achieve a 
lower score. The recently updated NEWS2 includes 
a second oxygen saturation scale which is intended 
for patients with hypercapnic respiratory failure 
(table 1). New onset of confusion has also been 
added to the level of consciousness index.1 The new 
oxygen saturation scale encourages the prescrip-
tion and delivery of oxygen to target saturations 
of 88%–92% in those with hypercapnia,7 while 
the original oxygen saturation scale is retained 
for patients without hypercapnia. This incorrectly 
assumes that patients with ECOPD without hyper-
capnia are not at risk of harm from excess oxygen; 
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Table 1 National Early Warning Score 2 (NEWS2) with risk score for 
oxygen saturations alone shown for scale 1 (normocapnic patients) 
and for scale 2 (hypercapnic patients)
nEWs2 scale 1 and original nEWs
(normocapnic patients)
nEWs2 scale 2
(hypercapnic patients)
oxygen saturations, % score oxygen saturations, % score
91 or less 3 83 or less 3
92–93 2 84–85 2
94–95 1 86–87 1
96 or more 0 88–92 0
    93 or more on air 0
    93–94 on O2 1
    95–96 on O2 2
    97 or more on O2 3
Scale 1 is the same as the original NEWS oxygen saturation index and is 
recommended for most patients including patients with COPD without hypercapnic 
respiratory failure. Scale 2 is recommended for patients with hypercapnic respiratory 
failure, whose target saturations are set lower (ie, 88%–92%).
Table 2 Indices that comprise news and DECAF scores, and rates of 
missing data in each cohort
derivation cohort Validation cohort
n=920 n=1725
NEWS and NEWS2
  Respiratory rate 0.33% 1.8%
  Oxygen saturation 0% 1.8%
  Supplemental oxygen 1.5% 0%
  Systolic blood pressure 0% 1.7%
  Pulse 0% 1.5%
  Level of consciousness 0% 1.8%
  Confusion (NEWS2 only) 0% 2.6%
  Temperature 0.54% 2.6%
DECAF score
  eMRCD score 0% 0%
  Eosinopenia 0% 0%
  Chest X-ray consolidation 0% 0%
  Acidaemia (pH <7.3) 0%* 0%*
  Atrial fibrillation 0% 0%
*In patients without an arterial blood gas, it was assumed that none had an 
acidaemia of <7.30 provided oxygen saturations were 93% or more while 
breathing room air. This was based on data from the derivation cohort: of 118 
patients meeting these criteria, none had an arterial pH of <7.30.
this can lead to CO2 retention
5 and is associated with increased 
mortality risk.8
Despite clear guidelines by the British Thoracic Society (BTS) 
promoting target saturations of 88%–92% in most patients with 
COPD,7 this is frequently not achieved in clinical practice.9 10 By 
assigning risk points to those with excess oxygen, NEWS2 will 
encourage the correct titration of oxygen in patients identified 
as at risk. Unfortunately, this is limited to patients confirmed 
to have hypercapnic respiratory failure on blood gas analysis 
and with clinician approval. Patients with hypercapnia will be at 
risk until blood gas analysis and clinical review, while those with 
normocapnia will remain at risk throughout. The BTS guide-
lines limit risk by recommending initial target saturations of 
88%–92%, but risk is not avoided as the target can be increased 
to 94%–98% following confirmation of normocapnia. In unse-
lected patients with a clinical diagnosis of ECOPD, there is 
randomised controlled trial (RCT) evidence that target satura-
tions of 88%–92% improve mortality.6 This favours adopting 
the second NEWS2 oxygen scale (88%–92%) in all patients with 
ECOPD, which would simplify the pathway facilitating imple-
mentation, and should greatly reduce the risk of excess oxygen 
use.
The DECAF (dyspnoea, eosinopenia, consolidation, acidaemia, 
atrial fibrillation) score is a risk stratification tool intended to be 
scored on admission and accurately predicts risk of death.11 12 It 
can be easily calculated at the bedside to guide treatment, such 
as hospital at home for low-risk patients.13 DECAF and NEWS2 
serve separate purposes in clinical practice: the former to risk 
assess patients accurately at admission and the latter to monitor 
patients for deterioration throughout admission. However, 
admission NEWS2 has not been compared with DECAF. The UK 
National Asthma and COPD Audit Programme currently relies 
on admission NEWS2 to allow case-mix adjustment for mortality 
risk; the superiority of DECAF would support its routine use 
for this purpose.14 Furthermore, if admission NEWS2 offered 
similar performance to DECAF in ECOPD, then the principle of 
parsimony would favour reliance on NEWS2 alone and render 
the DECAF score redundant.
The primary aim of this study was to assess the effect of modi-
fying NEWS2 to use the second oxygen saturation scale in all 
patients with ECOPD (target saturations of 88%–92%) with 
respect to inpatient alert frequency and appropriateness, and 
mortality prediction. We refer to this adapted version of NEWS2 
as ‘NEWS2All COPD’. Furthermore, we compare the performances 
of admission NEWS2All COPD, NEWS2, NEWS and the DECAF 
score.
METhods
The DECAF derivation and validation cohorts are composed of 
2645 consecutive admissions of unique patients with ECOPD 
to six UK hospitals with preadmission obstructive spirometry, 
age of 35 or older, and smoking history of 10 or more cigarette 
pack-years (ISRCTN 13946813 and 29082260).11 12
Collection of the DECAF and NEWS score indices, including 
confusion, was pre-specified in the original study protocols. The 
first set of NEWS indices was used, either from the accident and 
emergency (A+E) department, or the medical admissions unit 
if the patient bypassed A+E. Missing data were handled using 
multiple imputation as described previously.15 16 NEWS2 was 
initially calculated using scale 1 and scale 2 for normocapnic and 
hypercapnic patients, respectively (‘NEWS2’). NEWS2 was then 
re-calculated with the assumption that all patients with COPD 
should have oxygen saturations of 88%–92% (‘NEWS2All COPD’).
Patients were assigned to standard risk groups for each early 
warning score. For NEWS, NEWS2 and NEWS2All COPD, a score 
of 0 to 4 is low risk, 5 or 6 is moderate risk, and 7 or more is 
high risk. A patient with a NEWS of 5 or more should have at 
least hourly observations and be reviewed by a clinician with 
competencies in dealing with acute illness, such as a ward doctor. 
A score of 7 or more should prompt an emergency review, with 
continuous monitoring of observations.1 For the DECAF score, 
0 to 1 equates to a low in-hospital mortality risk, 2 is moderate 
risk, and 3 or more is high risk. Alert frequencies (NEWS, 
NEWS2, NEWS2All COPD score ≥5) and other proportions were 
compared with Fisher’s exact test. The performance of NEWS, 
NEWS2, NEWS2All COPD and DECAF for the prediction of 
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Table 3 Numbers of deaths by risk group for NEWS2, NEWS2 88%–92% and NEWS
All cohorts
Low-risk groups (0–4) Moderate-risk groups (5–6) high-risk groups (7+)
died All % died All % died All %
  NEWS2All COPD 35 1003 3.5 39 628 6.2 154 1014 15.2
  NEWS2 23 752 3.1 45 671 6.7 160 1222 13.1
  NEWS 25 670 3.7 57 730 7.8 146 1245 11.7
NEWS, NEWS2 and NEWS2 88%–92%: a score of 0 to 4 is low risk, 5 or 6 is moderate risk, and 7 or more is high risk.
Figure 1 Frequency of alerts for NEWS2All COPD, NEWS2 and NEWS. 
Figure shows the percentage of patients in each risk category, grouped 
together by early warning score. The first column in each group is 
NEWS2All COPD, the second is NEWS2 and the third is NEWS. P values were 
calculated using Fisher’s exact test. NEWS 5–6=medium risk, prompting 
urgent response by clinician/clinical team and minimum hourly 
observations. NEWS 7=high risk. Urgent response by clinician/clinical 
team, which may include critical care, and continuous monitoring or 
vital signs.
Figure 2 Histogram of NEWS scores. Figure shows all patients from 
the derivation and validation cohorts. The number of individuals is 
shown in the x-axis (‘count’) and the total NEWS2 score is shown on the 
y-axis. The grey lines separate low-risk (0–4), moderate-risk (5–6) and 
high-risk (7 or more) groups.
inpatient mortality was assessed and compared using the area 
under the receiver operating characteristic (AUROC) curve.17 
Calibration was assessed using the Hosmer-Lemeshow (HL) test 
and by visual assessment in calibration plots.18 19 Analyses were 
performed on IBM SPSS Statistics V.22 and SigmaPlot V.12.3.
rEsuLTs
Population and missing data
In 2645 patients, the mean (SD) age was 73.1 (10.2), 54% were 
women and the mean (SD) FEV1 was 45.1% (SD 18.2) predicted. 
Almost half were unable to leave the house unassisted (Extended 
Medical Research Council Dyspnoea score 5a or 5b=47%), and 
29.8% had consolidation on the admission chest X-ray. Further-
more, 17.9% of patients were acidaemic on the admission arte-
rial blood gas (ABG) analysis, and 10.1% had a pH of less than 
7.3. Comorbid conditions were common; 55.4% had a Charlson 
index of 2 or more, and 28.9% scored 3 or more. Overall inpa-
tient mortality was 8.6%; 96 in 920 (10.4%) in the derivation 
cohort and 132 in 1725 (7.7%) in the validation cohort.
A more detailed breakdown of patient characteristics by site 
and cohort is published elsewhere.11 12 There were no missing 
data for the primary outcome, inpatient mortality. Rates of 
missing data for indices were low and are shown in table 2.
risk groups and alerts
Inpatient mortality by risk group is shown in table 3. The 
percentage of patients classified as requiring an urgent review 
(score of 5 or more) for NEWS2All COPD, NEWS2 and NEWS was 
62.1%, 71.6% and 74.7% (middle column figure 1).
NEWS2All COPD resulted in a shift of total scores towards the 
lower risk range compared with NEWS2 (figure 2). NEWS2All 
COPD identified fewer patients requiring medical review relative 
to NEWS2 (9.5% absolute reduction), but the risk of death in 
the low-risk group was similar (3.5% and 3.1%, p=0.686).
A patient receiving excess oxygen may not necessarily require 
an urgent clinical review and should first have their oxygen 
titrated down to target range. For NEWS2, if excess oxygen 
scores were discounted, there was a significant reduction in the 
frequency of alerts for patients with a score of 5 or more (71.6% 
to 68.0%, p=0.005). For NEWS2All COPD, discounting excess 
oxygen reduced reviews in this group from 62.1% to 58.6% 
(p=0.010), with little difference in the percentage of deaths in 
the low-risk patient group (counting excess oxygen=3.5% vs 
discounting excess oxygen=3.6%, p=0.905). Of those patients 
who were assigned a low-risk NEWS2 or NEWS2All COPD score, 
none died that same day. This suggests that all of these patients 
were correctly categorised as low risk at the time; early warning 
scores are repeated with each set of observations and are likely 
to have risen in those who subsequently died.
Performance of admission dECAF and early warning scores 
for inpatient mortality
For all patients (n=2645), NEWS2All COPD was a stronger 
mortality predictor than NEWS (AUROC NEWS2All COPD=0.72, 
95% CI 0.68 to 0.76, vs NEWS=0.65, 95% CI 0.61 to 0.68; 
p<0.001). NEWS2All COPD showed a trend towards superiority 
compared with NEWS2 (AUROC NEWS2All COPD=0.72, 95% CI 
0.68 to 0.76, vs NEWS2=0.70, 95% CI 0.67 to 0.74; p=0.090).
Of interest, the addition of confusion to the ‘level of conscious-
ness’ component of NEWS2 accounted for part of the improved 
performance in NEWS2 compared with NEWS. For example, 
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Figure 3 Receiver operator curves for the DECAF score, NEWS2All COPD 
and NEWS all cohorts. Figure shows the performance of the DECAF, 
NEWS2All COPD, NEWS2 and NEWS scores. A higher area under the receiver 
operating characteristic curve (‘A’) shows better prediction. DECAF is 
not included in the derivation cohort, as this would unfairly favour its 
performance.
Table 4 Sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) at NEWS thresholds of 5 and 7
Low-risk group
(cut-off less than 5 for nEWs)
Low and moderate risk group combined
(cut-off less than 7 for nEWs)
sensitivity specificity nPV sensitivity specificity PPV
NEWS2All COPD 0.85 0.40 0.97 0.68 0.64 0.15
NEWS2 0.90 0.30 0.97 0.71 0.55 0.13
NEWS 0.89 0.27 0.96 0.64 0.55 0.12
DECAF 0.93 0.52 0.99 0.73 0.80 0.25
Figure 4 Calibration curves for DECAF, NEWS2All COPD, NEWS2 and 
NEWS in all cohorts. Figure shows calibration curves for NEWS2All COPD, 
NEWS2 and NEWS in all patients. DECAF is shown in the validation 
cohort, as inclusion of the derivation cohort would unfairly favour its 
performance. Predicted risk is shown on the y-axis which was calculated 
using logistic regression analysis to give individual’s mortality risk as a 
percentage. The x-axis shows the observed risk, which is a proportion 
of the number of patients who died within an assigned risk range. The 
slope of the equation should be near 1 (eg, for DECAF, the slope is 
1.038), and the intercept should be near 0 (for DECAF, this is 0.0022). 
The R2 represents the correlation between the predicted risk and 
observed risk using Pearson’s correlation, with scores closest to 1 
showing maximum correlation.
when scored without confusion, the AUROC for NEWS2All COPD 
was only 0.68 (95% CI 0.64 to 0.71) which is significantly worse 
than NEWS2All COPD scored with confusion (p<0.001).
DECAF provided optimal prediction of inpatient mortality, 
and was superior to NEWS2 and NEWS2All COPD in terms of 
performance as shown in figure 3 (further data in online supple-
mentary table 1).
Table 4 shows the performance of early warning scores at 
low-risk and high-risk NEWS thresholds (5 and 7), with the 
DECAF score the gold standard. The positive predictive value 
(PPV) and negative predictive value (NPV) most inform the clini-
cian: the PPV is the chance of a patient dying if they score above 
the threshold, while the NPV is the chance of a patient surviving 
if they score below the threshold. Sensitivity is the proportion of 
those who died that were correctly identified as at risk (above the 
threshold), while the specificity looks at the proportion of those 
who survived, identified as not at risk (below the threshold).
In the low-risk group, a higher sensitivity and NPV is desir-
able. With regards to sensitivity, NEWS2 performed optimally, 
while both NEWS2 scores performed equally well for NPV. In 
the high-risk group, a high specificity and PPV is desirable, for 
which NEWS2All COPD performed optimally.
Calibration describes how well individuals’ predicted risks 
from a logistic regression model agree with the observed risk in 
terms of the proportion of individuals affected. The goodness of 
fit can be measured with the HL test, with poor fit indicated by 
a small calculated p value. DECAF, NEWS2All COPD and NEWS 
were well calibrated with HL statistics of p=0.209, p=0.237 
and p=0.736. NEWS2 was not well calibrated, with an HL 
statistic of p=0.048.
Calibration curves are shown in figure 4. A good prognostic 
tool should cover a range of risks, have an intercept close to zero 
and a slope of one, and have the intersection of predicted and 
observed risk close to the line (shown by the dots). NEWS2All 
COPD was well calibrated and covered a larger range of risks than 
other early warning scores.
disCussion
Patients admitted with ECOPD have a modest in-hospital 
mortality rate (3.9%–4.3%),10 20 but frequently trigger alerts 
on the National Early Warning Scale (NEWS). This can place a 
substantial burden on healthcare professionals, create compla-
cency and promote excess oxygen use in those who are at partic-
ular risk of its harmful effects.6 In this study, NEWS2 showed 
superior discrimination for mortality to NEWS, but only 
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reclassified 3.1% as not requiring a review, based on an alert 
trigger of 5 or more. NEWS2All COPD, adopting target saturations 
of 88%–92% and scale 2 of the NEWS2 tool for all patients, 
led to an absolute reduction in alert frequency of 12.6%. In 
clinical practice, titrating down oxygen prior to alerts may be 
appropriate; this approach decreased alerts by 16.1%. The 
performance of NEWS2All COPD was similar to NEWS2, with no 
increased risk of death in the low-risk group. Of key importance, 
there were no deaths on the same day that patients were classi-
fied as not requiring review.
DECAF was prognostically superior to all scores, showed the 
most consistent performance and was well calibrated. Accu-
rate mortality prediction informs clinical decision-making; the 
low-risk DECAF group was larger with a lower risk of death 
than seen with other scores, which makes DECAF suitable for 
the identification of patients for early discharge or hospital at 
home services. Additionally, in the National Asthma and COPD 
Audit, baseline mortality risk is being quantified by the NEWS2 
score, but our results show NEWS2 should not be used in place 
of the DECAF score for this purpose.
Eligibility criteria were broad and rates of missing data were 
low, with robust data analyses, including methods to deal with 
missing data. The assessment of the NEWS score was pre-spec-
ified, as was the assessment of confusion; therefore, there is no 
bias in the subsequent re-coding of NEWS2. Furthermore, in 
both cohorts, the inclusion of NEWS indices was pre-specified, 
and data were collected prior to and/or without knowledge of 
the (objective) outcome. For the AUROC curve comparison, 
DECAF was compared with NEWS iterations only in the vali-
dation cohort; comparing performance in the derivation cohort 
would have introduced bias in favour of the DECAF score. A key 
strength is that our population was well described, with respi-
ratory specialist confirmation of exacerbation and spirometric 
confirmation of COPD. These results may not apply to those 
with presumed ECOPD without obstructive spirometry (patients 
misdiagnosed with COPD). In our study, considerable efforts 
were made to obtain previous lung function results: we checked 
primary and secondary paper and electronic records before 
concluding spirometry was unavailable.
Our study has the following limitations. Scores were compared 
using admission data only. For the comparison with the DECAF 
score, using admission data is appropriate as we are assessing the 
tools’ performance as a guide to inform clinical decision-making 
at the point of admission. However, for NEWS the inclusion of 
multiple measures would have added further useful data.
‘NEWS2-without confusion’ has been compared with NEWS 
by Hodgson and others, in a large cohort of patients.21 They 
reported concerns that high-risk patients were inappropriately 
downgraded by NEWS2. However, NEWS2 was calculated from 
NEWS, which does not include confusion. This is an important 
omission as we have shown that confusion offers additional 
prognostic benefit, and inclusion of confusion may have resulted 
in fewer patients being downgraded. Furthermore, time to death 
was not reported: in our study, no low-risk patients died the 
same day, which supports correct risk categorisation. In common 
with other studies assessing similar early warning scores (such as 
Salford NEWS),22 Hodgson et al23 used ICD-10 codes to iden-
tify patients, which are known to be inaccurate.
A recent retrospective study by Pimentel et al24 offers the 
advantage of capture of sequential early warning scores in 
251 266 acute adult admissions. Again, reliance on coding limits 
data quality in terms of case ascertainment. Again, confusion was 
not included, and therefore NEWS2 was not correctly scored. 
In 48 898 patients with conditions that were associated with 
risk of hypercapnia based on ICD-10 codes, ‘NEWS2-without 
confusion’ was slightly inferior to NEWS for identifying death 
within 24 hours. In a subgroup of 1394 patients with confirmed 
hypercapnia, ‘NEWS2-without confusion’ offered similar 
discrimination and a higher PPV than NEWS. In common with 
our study, ‘NEWS2-without confusion’ generated fewer alerts, 
and mortality rates were low on the same day as patients having 
low-risk assessments. Our study differs in that we only included 
patients with confirmed COPD, NEWS2 was correctly scored 
and case ascertainment was robust.
While no patient should receive a diagnosis of COPD without 
obstructive spirometry, we acknowledge that this does occur 
and that our results may not be generalisable to such patients. 
However, we highlight that the Austin RCT showed that target 
SpO2 88%–92% in all patients with a presumed diagnosis 
of ECOPD at ambulance pick-up was associated with lower 
mortality, and this included patients without a spirometry-con-
firmed diagnosis of COPD.6
An important limitation of this and other studies of NEWS2 is 
that we did not observe NEWS2 in practice. Real-time recording 
of NEWS2 may result in changes in clinical behaviour. For 
example, while the performance of NEWS2All COPD and NEWS2 
was similar in our study, the reduction in false alerts with 
NEWS2All COPD could result in the more timely clinical assessment 
of other patients and hence a positive clinical outcome. Prospec-
tive randomised studies are required to address these points,25 
and to see if the use of NEWS2All COPD leads to improvements in 
mortality by preventing excess oxygen prescribing, but would be 
challenging to perform. Mortality was high in this study, though 
appropriate given the higher levels of comorbidity, pneumonia 
and frailty in our cohort compared with UK national audit data 
collected at a similar time.
The current BTS oxygen guidelines recommend initial target 
saturations of 88%–92% in patients with COPD. NEWS2 
requires confirmation of hypercapnia before the alternative 
oxygen saturation scale is activated and should only be instigated 
by a clinician. Of concern, the NEWS2 implementation guidance 
and NEWS2 chart may result in many patients receiving excess 
oxygen prior to ABG analysis or clinician review. RCT data show 
a mortality benefit in those treated with oxygen target saturations 
88%–92% at the point of ambulance pick-up. These patients did 
not have baseline ABG analysis prior to oxygen treatment, and 
this approach was beneficial even though a substantial propor-
tion of patients were subsequently described as not having 
COPD.6 RCTs have identified increases in mortality with excess 
oxygen in patients with a range of acute medical presentations 
even where there is no risk of hypercapnia.26 Using NEWS2All 
COPD in all patients with ECOPD could offer improved prognostic 
performance and calibration, with significantly fewer alerts, and 
lead to a reduction in harm from excess oxygen delivery in this 
at-risk population.
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